Have you received REBYOTA to keep recurrent C. diff from coming back? SHARE YOUR STORY>

REBYOTA^™ Support & Resources

Ferring Pharmaceuticals may offer financial assistance to qualified patients treated with REBYOTA.

REBYOTA Co-pay Program

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100^a for each REBYOTA prescription.

^aAvailable only for patients who meet eligibility requirements. The program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

- For commercially insured individuals whose insurance plans cover REBYOTA
- Must be 18 years of age or older
- Offer valid only in the US
- Must have been administered REBYOTA for an FDA approved indication

See additional terms and conditions below.

To enroll in the REBYOTA Co-pay Program, please speak with your doctor.

For additional assistance, call 1-877-REBYOTA

This offer is not contingent on any past, present or future purchase, including refills. This REBYOTA Co-pay Program offer is good for use only upon the administration of REBYOTA (“Product”) for an FDA approved indication in the US. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations for REBYOTA including applicable co-payments, coinsurance, and deductibles. Ferring will provide coverage maximum cap of up to $5,000 per dose with a maximum benefit of $10,000 per patient per calendar year. The value of this offer may not exceed the amount of the patient’s out-of-pocket costs for the Product. Documentation including Explanation of Benefits (EOB) will be required. The REBYOTA Co-pay Program is not health insurance. Offer is invalid for all transactions and claims submitted more than 180 days following the date of service. The REBYOTA Co-pay Program is not valid for Product reimbursed in whole or in part by Medicare, Medicaid, or a Medicare Part D plan, TRICARE, US Department of Veteran Affairs, US Department of Defense, the Commonwealth of Puerto Rico, government health insurance plan, or any other federal or state-funded healthcare benefit program. The REBYOTA Co-pay Program is void where prohibited by law, taxed, or restricted, as in the States of California and Massachusetts. The REBYOTA Co-pay Program is not transferable and is limited to one program benefit per patient. No substitutions are permitted. The REBYOTA Co-pay Program benefit cannot be combined with any other co-pay program, free trial, discount, prescription savings card, or other offer. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. Ferring Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. Offer expires 12/31/24.

REBYOTA Patient Assistance Program^a

You may be eligible to receive REBYOTA at no cost if you qualify for the Ferring REBYOTA Patient Assistance Program (PAP). Simply ask your doctor’s office to enroll on your behalf through REBYOTA Connect.

- You must be prescribed REBYOTA for an FDA approved indication
- You reside in the US
- You are being treated by a US-licensed healthcare provider
- Income restrictions apply

See additional terms and conditions below.

To learn more about the REBYOTA Patient Assistance Program and to see if you qualify, please speak with your doctor.

The REBYOTA Patient Assistance Program is only available for qualified patients enrolled in REBYOTA Connect.

Participation in the PAP is free. Ferring does not collect any fees from people seeking assistance through PAP.

Assistance is provided in the form of free product shipped to site of administration or reimbursement for the invoiced cost of the product if processed after product has been administered. If assistance is in the form of free product, REBYOTA must be secured at the site of administration until the qualified PAP patient’s treatment date, and the medicine must be provided only to the eligible patient at no charge of any kind for the product. If product administration occurs and patient was qualified for PAP, reimbursement for the invoiced cost of the product can occur for Healthcare Providers or Specialty Pharmacies after they have provided supporting documentation for the product cost only in addition to a completed Reimbursement Request form. The REBYOTA PAP only covers the cost of the product and not administration or other services.

Any medications supplied by Ferring as a result of enrollment in the PAP are for the use of the named patient only and will not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement.

If REBYOTA is no longer medically necessary for a qualified patient’s treatment or if the patient’s insurance or financial status changes, this must be reported to REBYOTA Connect.

If patient authorization is signed, electronic verification of a patient’s financial status is available to help determine eligibility,

PAP beneficiaries with government insurance are eligible to obtain medication through the end of the calendar year. PAP beneficiaries with commercial insurance are eligible to obtain medication for up to 12 months.

Healthcare Providers may not submit claims or payment from this medication through an insurance plan of any kind. Patients may not seek true out-of-pocket (TrOOP) or other insurance credit for medication provided through the PAP.

If applicable, PAP recipients will have their health plans receive written notification.

Ferring may change or cancel the PAP at any time and Ferring reserves the right to terminate a patient’s enrollment in the PAP at any time.

If you were screened for additional financial assistance offerings through the REBYOTA Connect Program and were informed you do not qualify, please click here to file an appeal.

Patient Testimonials

See how REBYOTA has helped people keep recurrent C. diff infection from coming back. These are some of their inspiring stories.

Melissa’s story

“Had this treatment been available sooner, I would have asked for it.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Melissa was compensated for her time. Individual results may vary.

Melissa’s Story Video: Her Journey to REBYOTA Treatment

Freda’s story

“I just knew that if I had C. diff again, I wasn’t going to survive. But my C. diff didn’t come back after I had my treatment.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Freda was compensated for her time. Individual results may vary.

Freda’s Story Video: Her Journey to REBYOTA Treatment

Patricia’s story

“For me it was one dose and one visit, and that was it. I was able to hug and squeeze my girls again.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Patricia was compensated for her time. Individual results may vary.

Patricia’s Story Video: Her Journey to REBYOTA Treatment

Marty’s story

“After REBYOTA, my symptoms never came back. I’ve had no recurrences.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Marty was compensated for his time. Individual results may vary.

Marty’s Video: His Road to Recovery with REBYOTA

Frequently Asked Questions

What is REBYOTA?

REBYOTA is the first and only single-dose, FDA approved microbiome-based treatment to keep recurrent C. diff infection
from coming back, after you’ve already taken antibiotics.¹
- A single-dose treatment administered in your doctor’s office in minutes
- REBYOTA is manufactured through a process that tests for disease-causing organisms and viruses for product safety
- Delivered rectally to your gut microbiome, where it’s needed
- No laxatives/bowel prep, fasting, anesthesia, or colonoscopy are required¹
REBYOTA is a liquid mix of trillions of live microbes—including Bacteroides—sourced from the stool of qualified human donors. Each dose and donor have been tested and screened to help address product safety.

Before Treatment

During Treatment

After Treatment

Insurance/Financial Support

Commercially insured, eligible patients may pay as little as $100^a for each REBYOTA prescription. You must meet eligibility requirements, and terms and conditions apply. To enroll in the REBYOTA Co-pay Program, please speak with your doctor.

For additional assistance, call 1-877-REBYOTA.

^aAvailable only for patients who meet eligibility requirements. Programs do not cover the cost of administration, office visits,
or any associated costs. Terms and conditions apply. Offer expires 12/31/24.
The Program is for commercially insured patients whose insurance plans cover REBYOTA.
- Must be 18 years of age or older
- Offer valid only in the US
- You are being treated by a US-licensed healthcare provider
- Offer expires 12/31/24
^aAvailable only for patients who meet eligibility requirements. Programs do not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.
You may be eligible to receive REBYOTA at no cost^a if you qualify for the Ferring REBYOTA Patient Assistance Program.
The program is open to uninsured and underinsured patients who meet the following eligibility criteria:
- You must be prescribed REBYOTA for an FDA approved indication
- You reside in the US
- You are being treated by a US licensed healthcare provider
- Income restrictions apply
^aAvailable only for patients who meet eligibility requirements. Programs do not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

This is Patricia’s Story

I was finally able to tuck my girls into bed again. I read them a story and had lots of snuggles.

- Patricia, Clinical Study Patient

Watch Patricia’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Patricia was compensated for her time. Individual results may vary.

Have you also been treated with REBYOTA? SHARE YOUR STORY>

Follow these routines for cleanliness to keep your home and those you care about safe^2,3:
- Hand hygiene. Wash hands with soap and warm water before and after using the bathroom, and before and after eating
- Disinfect and clean thoroughly. Use products that contain chlorine bleach to kill bacteria; ordinary alcohol-based cleansers or sanitizers do not kill C. diff
- Control contact. People with C. diff infection should be isolated in a private room, with a bathroom only they will use
- Protective gear. Disposable gloves or gowns may be required for visitors when near hospitalized patients with C. diff infection

Helpful Resources

Resources to help you and others (including caregivers) who may be coping with C. diff infection.

Advocate for a Loved One

Here is a Caregiver Checklist to help get you started.

Download

Track Your Progress

A diary for recording your
C. diff infection experiences.

Download

Join an Online Research Panel

Have you suffered with C. diff or cared for someone who has? Or have you recently been treated with REBYOTA? If so, please join an online research panel and help others living with C. diff.

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Build Your Guide

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

Consent(Required)

I CONSENT(Required)

By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

References

REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infection. Am J Gastroenterol. 2013;108(4):478-498.
McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48.

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

You are leaving REBYOTA.com

The link you have selected will direct you to a site or resource outside of our website.
Thank you.

Okay

REBYOTA™ Support & Resources

REBYOTA Co-pay Program

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100a for each REBYOTA prescription.

REBYOTA Patient Assistance Programa

You may be eligible to receive REBYOTA at no cost if you qualify for the Ferring REBYOTA Patient Assistance Program (PAP). Simply ask your doctor’s office to enroll on your behalf through REBYOTA Connect.

Patient Testimonials

Melissa’s story

Freda’s story

Patricia’s story

Marty’s story

Share Your REBYOTA Treatment Story

Frequently Asked Questions

What is REBYOTA?

Before Treatment

During Treatment

After Treatment

Insurance/Financial Support

This is Patricia’s Story

Helpful Resources

Advocate for a Loved One

Track Your Progress

Join an Online Research Panel

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

References

Please see Important Safety Information and full Prescribing Information

INDICATION

Important Safety Information

You are leaving REBYOTA.com

REBYOTA^™ Support & Resources

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100^a for each REBYOTA prescription.

REBYOTA Patient Assistance Program^a